Assembly Biosciences Exercises U.S. Profit-Share Option for Herpes Program With Gilead
Gilead Sciences Inc GILD
News
FDA Approves Gilead Sciences' Bixlenvo for Certain Adults With HIV
Lakefront Biotherapeutics Autoimmune Disorder Pemphigus Treatment Gets FDA Orphan Drug Designation
Your prescription drugs shouldn't cost more than your mortgage. Inside the broken math that got us here.
Gilead Sciences Swings to 2Q Loss on R&D Costs, HIV-Drug Sales Lift Revenue
Gilead Sciences Down Over 4%, on Pace for Largest Percent Decrease Since July 2025 — Data Talk
Gilead Gets FDA Approval for Treatment for Aggressive Form of Breast Cancer
Merck, Gilead End Lung Cancer Trial, Report Positive Data From HIV Drug Trials
Gilead Sciences Gets FDA Green Light for Chronic HDV Drug
Gilead Gets Positive Opinion From European Regulators on Breast-Cancer Treatment
Moderna's stock has rallied on hantavirus research that is 'early-stage' in nature
Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
Arcus Biosciences Discontinues Lung Cancer Trial With Gilead
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion — Update
Gilead Extends Deadline on Tender Offer to Acquire Arcellx
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets — Update
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
Gilead shows belief in its partner's cancer treatment with $7.8 billion buyout
Gilead Sciences to Buy Arcellx in Deal Valuing Biotech at $7.8 Billion — Update
Gilead Sciences to Buy Arcellx in Deal Valuing Biotech at $7.8 Billion
United States